Pin Xiang, PharmD, MS

  • 2Articles
  • 5.5KReads
  • 2024–2025Active
  • 9Collaborators
  • 10Citations

About

Pin Xiang, PharmD, MS is affiliated with Boehringer Ingelheim Pharmaceutical Inc, Ridgefield, Connecticut. Pin Xiang has authored or co-authored 2 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2024 and 2025. Their work focuses on Schizophrenia/Schizoaffective Disorders, Cognition, and Psychotic Disorders.

Publications

JCP
The Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US
Original Research

The Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US

August 11, 2025

Medical Expenditure Panel Survey data showed that over half of adults with schizophrenia report cognitive impairments, which were associated with higher healthcare costs and lower quality of life.
, , , et al
JCP
Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia
Review Article

Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia

August 21, 2024

Patients with schizophrenia and cognitive impairment had a 100% increase in relapse-related hospitalizations and ER visits versus patients with no (or only mild) cognitive impairment.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe